The influence of dysfunctional signaling and lipid homeostasis in mediating the inflammatory responses during atherosclerosis

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1852, Issue 7, 2015, Pages 1498-1510

  Buckley, Melanie L ^a   Ramji, Dipak P ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Atherosclerosis; Cytokines; Immune cells; Inflammation; Lipoproteins; Signaling

Indexed keywords

CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; STRESS ACTIVATED PROTEIN KINASE;

ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; ATHEROSCLEROTIC PLAQUE RUPTURE; CELL FUNCTION; CELL HETEROGENEITY; CELLULAR IMMUNITY; DENDRITIC CELL; DISEASE COURSE; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOPATHOGENESIS; INTRACELLULAR SIGNALING; LIPID HOMEOSTASIS; MACROPHAGE; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; RUPTURE; T LYMPHOCYTE; ANIMALS; HOMEOSTASIS; HUMANS; IMMUNOLOGY; INFLAMMATION; LIPID METABOLISM; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; ATHEROSCLEROSIS; HOMEOSTASIS; HUMANS; INFLAMMATION; LIPID METABOLISM; SIGNAL TRANSDUCTION;

EID: 84928555600     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2015.04.011     Document Type: Review

References (192)

1. Go A.S., Mozaffarian D., Roger V.L., Benjamin E.J., Berry J.D., Blaha M.J., et al. Heart disease and stroke statistics-2014 update: A report from the American Heart Association. Circulation 2014, 129:399-410.
2. McLaren J.E., Michael D.R., Ashlin T.G., Ramji D.P. Cytokines, macrophage lipid metabolism and foam cells: Implications for cardiovascular disease therapy. Prog. Lipid Res. 2011, 50:331-347.
3. Tomkin G.H., Owens D. The chylomicron: relationship to atherosclerosis. Int. J. Vasc. Med. 2012, 2012:784536.
4. Kovacic S., Bakran M. Genetic susceptibility to atherosclerosis. Stroke Res. Treat. 2012, 2012:362941.
5. Lagace T.A. PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells. Curr. Opin. Lipidol. 2014, 25:387-393.
6. Zhang L., Reue K., Fong L.G., Young S.G., Tontonoz P. Feedback regulation of cholesterol uptake by the LXR-IDOL-LDLR axis. Arterioscler. Thromb. Vasc. Biol. 2012, 32:2541-2546.
7. Golstein J.L., Brown M.S. The LDL receptor. Arterioscler. Thromb. Vasc. Biol. 2009, 29:431-438.
8. Ono K. Current concept of reverse cholesterol transport and novel strategy for atheroprotection. J. Cardiol. 2012, 60:339-343.
9. Phillips M.C. Molecular mechanism of cellular cholesterol efflux. J. Biol. Chem. 2014, 29:24020-24029.
10. Michael D.R., Ashlin T.G., Buckley M.L., Ramji D.P. Macrophages, lipid metabolism and gene expression in atherogenesis: A therapeutic target of the future?. J. Clin. Lipidol. 2012, 7:37-48.
11. Michael D.R., Ashlin T.G., Buckley M.L., Ramji D.P. Liver X receptors, atherosclerosis and inflammation. Curr. Atheroscler. Rep. 2012, 14:284-293.
12. Spann N.J., Garmire L.X., McDonald J.G., Myers D.S., Milne S.B., Shibata N., et al. Regulated accumulation of desmosterol integrates macrophage lipid metabolism and inflammatory responses. Cell 2012, 15:138-152.
13. Ouimet M., Franklin V., Mak E., Liao X., Tabas I., Marcel Y.L. Autophagy regulates cholesterol efflux from macrophage foam cells via lysosomal acid lipase. Cell Metab. 2011, 13:655-667.
14. Plutzky J. The PPAR-RXR transcriptional complex in the vasculature: energy in the balance. Circ. Res. 2011, 108:1002-1016.
15. Cheang W.S., Fang X., Tian X.Y. Pleiotropic effects of peroxisome proliferator-activated receptor γ and δ in vascular diseases. Circ. J. 2013, 77:2664-2671.
16. Rader D.J., Hovingh G.K. HDL and cardiovascular disease. Lancet 2014, 384:618-625.
17. Kingwell B.A., Chapman M.J., Konhish A., Miller N.E. HDL-targeted therapies: progress, failures and future. Nat. Rev. Drug Discov. 2014, 13:445-464.
18. Van Eck M. ATP-binding cassette transporter A1: key player in cardiovascular and metabolic disease at local and systemic level. Curr. Opin. Lipidol. 2014, 25:297-303.
19. Calabresi L., Gomaraschi M., Simonelli S., Bernini F., Franceschini G. HDL and atherosclerosis: Insights from inherited HDL disorders. Biochim. Biophys. Acta 2015, 185:13-18.
20. Getz G.S., Reardon C.A. Animal models of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2012, 32:1104-1115.
21. Zadelaar S., Kleemann R., Verschuren L., de Vries-Van der Weij J., van der Hoorn J., Princen H.M., Kooistra T. Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler. Thromb. Vasc. Biol. 2007, 27:1706-1721.
22. Greenow K., Pearce N.J., Ramji D.P. The key role of apolipoprotein E in atherosclerosis. J. Mol. Med. 2005, 83:329-342.
23. Lin S., Lin Y., Nery J.R., Urich M.A., Breschi A., Davis C.A., et al. Comparison of the transcriptional landscapes between human and mouse tissues. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:17224-17229.
24. Seok J., Warren H.S., Cuenca A.G., Mindrinos M.N., Baker H.V., Xu W., et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:3507-3512.
25. Bryan M.T., Duckles H., Feng S., Hsiao S.T., Kim H.R., Serbanovic-Canic J., Evans P.C. Mechanoresponsive networks controlling vascular inflammation. Arterioscler. Thromb. Vasc. Biol. 2014, 34:2199-2205.
26. Tousoulis D., Simpoulou C., Papageorgiou N., Oikonomou E., Hatzis G., Siasos G., Tsiamis E., Stefanadis C. Endothelial dysfunction in conduit arteries and in microcirculation, Novel therapeutic approaches. Pharmacol. Ther. 2014, 144:253-267.
27. Wen Y., Leake D.S. Low density lipoprotein undergoes oxidation within lysosomes in cells. Circ. Res. 2007, 100:1337-1343.
28. Frostegård J. Immunity, atherosclerosis and cardiovascular disease. BMC Med. 2013, 11:117.
29. Wraith K.S., Magwenzi S., Aburima A., Wen Y., Leake D.S., Naseem K.M. Oxidized low-density lipoproteins induce rapid platelet activation and shape change through tyrosine kinase and Rho kinase-signaling pathways. Blood 2013, 122:580-589.
30. Libby P., Lichtman A.H., Hansson G.K. Immune effector mechanisms implicated in atherosclerosis: From mice to humans. Immunity 2013, 38:1092-1104.
31. Bae Y.S., Lee J.H., Choi S.H., Kim S., Almazan F., Witztum J.L., Miller Y.I. Macrophages generate reactive oxygen species in response to minimally oxidized low-density lipoprotein: toll-like receptor 4- and spleen tyrosine kinase-dependent activation of NADPH oxidase 2. Circ. Res. 2009, 104:201-218.
32. Choi S.H., Harkewicz R., Lee J.H., Boullier A., Almazan F., Li A.C., Witztum J.L., Bae Y.S., Miller Y.I. Lipoprotein accumulation in macrophages via toll-like receptor-4-dependent fluid phase uptake. Circ. Res. 2009, 104:1355-1363.
33. Koenen R.R., Weber C. Therapeutic trageting of chemokine interactions in atherosclerosis. Nat. Rev. Drug Discov. 2010, 141:141-153.
34. Weber C., Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat. Med. 2011, 17:1410-1422.
35. Moore K.J., Sheedy F.J., Fisher E.A. Macrophages in atherosclerosis: a dynamic balance. Nat. Rev. Immunol. 2013, 13:709-721.
36. Zernecke A., Weber C. Chemokines in atherosclerosis: proceedings resumed. Arterioscler. Thromb. Vasc. Biol. 2014, 34:742-750.
37. Cole J.E., Kassiteridi C., Monaco C. Toll-like receptors in atherosclerosis: a "Pandora's box" of advances and controversies. Trends Pharmacol. Sci. 2013, 34:629-636.
38. Michelsen K.S., Wong M.H., Shah P.K., Zhang W., Yano J., Doherty T.M., Akira S., Rajavashisth T.B., Ardity M. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:10679-10684.
39. Mullick A.E., Tobias P.S., Curtiss L.K. Modulation of atherosclerosis in mice by Toll-like receptor 2. J. Clin. Invest. 2005, 115:3149-3156.
40. Kim T.W., Febbraio M., Robinet P., Dugar B., Greene D., Cerny A., et al. The critical role of IL-1 receptor-associated kinase 4-mediated NF-κB activation in modified low-density lipoprotein-induced inflammatory gene expression and atherosclerosis. J. Immunol 2011, 186:2871-2880.
41. Lutgens E., Lievens D., Beckers L., Wijnands E., Soehnlein O., Zernecke A., et al. Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile. J. Exp. Med. 2010, 207:391-404.
42. Richards M.R., Black A.S., Bonnet D.J., Barish G.D., Woo C.W., Tabas I., Curtiss L.K., Tobias P.S. The LPS2 mutation in TRIF is atheroprotective in hyperlipidemic low density lipoprotein receptor knockout mice. Innate Immun. 2013, 19:20-29.
43. Björkbacka H., Kunjathoor V.V., Moore K.J., Koehn S., Ordija C.M., Lee M.A., Means T., Halmen K., Luster A.D., Golenbock D.T., Freeman M.W. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat. Med. 2004, 10:416-421.
44. Duewell P., Kono H., Rayner K.J., Sirois C.M., Vladimer G., Bauernfeind F.G., et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010, 464:1357-1361.
45. Menu P., Pellegrin M., Aubert J.F., Bouzourene K., Tardivel A., Mazzolai L., Tschopp J. Atherosclerosis in ApoE-deficient mice progresses independently of the NLRP3 inflammasome. Cell Death Dis. 2011, 2:e137.
46. Canton J., Neculai D., Grinstein S. Scavenger receptors in homeostasis and immunity. Nat. Rev. Immunol. 2013, 13:621-636.
47. Kzhyshkowska J., Neyen C., Gordon S. Role of macrophage scavenger receptors in atherosclerosis. Immunobiology 2012, 217:492-502.
48. Febbraio M., Podrez E.A., Smith J.D., Hajjar D.P., Hazen S.L., Hoff H.F., Sharma K., Silverstein R.L. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J. Clin. Invest. 2000, 105:1049-1056.
49. Makinen P.I., Lappalainen J.P., Heinonen S.E., Leppanen P., Lahteenvuo M.T., Aarnio J.V., Heikkila J., Turunen M.P., Ylä-Herttuala S. Silencing of either SR-A or CD36 reduces atherosclerosis in hyperlipidaemic mice and reveals reciprocal upregulation of these receptors. Cardiovasc. Res. 2010, 88:530-538.
50. Manning-Tobin J.J., Moore K.J., Seimon T.A., Bell S.A., Sharuk M., Alvarez-Leite J.I., de Winther M.P., Tabas I., Freeman M.W. Loss of SR-A and CD36 activity reduces atherosclerotic lesion complexity without abrogating foam cell formation in hyperlipidemic mice. Arterioscler. Thromb. Vasc. Biol. 2009, 29:19-26.
51. Moore K.J., Kunjathoor V., Koehn S.L., Manning J.J., Tseng A.A., Silver J.M., McKee M., Freeman M.W. Loss of receptor-mediated uptake via scavenger receptor A or CD36 pathways does not ameliorate atherosclerosis in hyperlipidemic mice. J. Clin. Invest. 2005, 115:2192-2201.
52. Michael D.R., Ashlin T.G., Davies C.S., Gallagher H., Stoneman T.W., Buckley M.L., Ramji D.P. Differential regulation of macropinocytosis in macrophages by cytokines: Implications for foam cell formation and atherosclerosis. Cytokine 2013, 64:357-361.
53. Bentzon J.F., Otsuka F., Virmani R., Falk E. Mechanisms of plaque formation and rupture. Circ. Res. 2014, 114:1852-1866.
54. Zhu X., Owen J.S., Wilson M.D., Li H., Griffiths G.L., Thomas M.J., Hiltbold E.M., Fessler M.B., Parks J.S. Macrophage ABCA1 reduces Myd88-dependent Toll-like receptor trafficking to lipid rafts by reduction of lipid raft cholesterol. J. Lipid Res. 2010, 51:3196-3206.
55. Yvan-Charvet L., Welch C., Pagler T.A., Ranalletta M., Lamkanfi M., Han S., Ishibashi M., Li R., Wang N., Tall A.R. Increased inflammatory gene expression in ABC transporter-deficient macrophages: free cholesterol accumulation, increased signaling via toll-like receptors, and neutrophil infiltration of atherosclerotic lesions. Circulation 2008, 118:1837-1847. (118).
56. Tabas I. Macrophage death and defective inflammation resolution in atherosclerosis. Nat. Rev. Immunol. 2010, 10:36-46.
57. Feng B., Yao P.M., Li Y.K., Devlin C.M., Zhang D.J., Harding H.P., Sweeney M., et al. The endoplasmic reticulum is the site of cholesterol-induced cytotoxicity in macrophages. Nat. Cell Biol. 2003, 5:781-792.
58. Van Vré E.A., Ait-Oufella H., Tedgui A., Mallat Z. Apoptotic cell death and efferocytosis in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2012, 32:887-893.
59. Szondy Z., Garabuczi E., Joós G., Tsay G.J., Sarang Z. Impaired clearance of apoptotic cells in chronic inflammatory diseases: therapeutic implications. Front. Immunol. 2014, 5:354.
60. Witztum J.L., Lichman A.H. The influence of innate and adaptive immune responses on atherosclerosis. Annu. Rev. Pathol. 2014, 9:73-102.
61. Newby A. Proteinases and plaque rupture: unblocking the road to translation. Curr. Opin. Lipidol. 2014, 25:358-366.
62. Newby A. Matrix metalloproteinase inhibition therapy for vascular diseases. Vasc. Pharmacol. 2012, 56:232-244.
63. Silvestre-Roig C., de Winther M.P., Weber C., Daemen M.J., Lutgens E., Soehnlein O. Atherosclerotic plaque destabilization: mechanisms, models, and therapeutic strategies. Circ. Res. 2014, 114:214-226.
64. McLaren J.E., Ramji D.P. Interferon gamma: A master regulator of atherosclerosis. Cytokine Growth Factor Rev. 2009, 20:125-135.
65. Muslin A.J. MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets. Clin. Sci. 2008, 115:203-218.
66. Kyriakis J.M., Avruch J. Mammalian MAPK signal transduction pathways activated by stress and inflammation: a 10-year update. Physiol. Rev. 2012, 92:689-737.
67. Pamukcu B., Lip G.Y., Shantsila E. The nuclear factor-kappaB pathway in atherosclerosis: a potential therapeutic target for atherothrobotic vascular disaese. Thromb. Res. 2011, 128:117-123.
68. Ghigo A., Morello F., Perino A., Hirsch E. Therapeutic applications of PI3K inhibitors in cardiovascular diseases. Future Med. Chem. 2013, 5:479-492.
69. Zhou X., Yin Z., Guo X., Hajjar D.P., Han J. Inhibition of ERK1/2 and activation of liver X receptor synergistically induce macrophage ABCA1 expression and cholesterol efflux. J. Biol. Chem. 2010, 285:6316-6326.
70. Li N., McLaren J.E., Michael D.R., Clement M., Fielding C.A., Ramji D.P. ERK is integral to the IFN-gamma-mediated activation of STAT1, the expression of key genes implicated in atherosclerosis, and the uptake of modified lipoproteins by human macrophages. J. Immunol. 2010, 185:3041-3048.
71. Salter R.C., Ashlin T.G., Kwan A.P.L., Ramji D.P. ADAMTS proteases: key roles in atherosclerosis?. J. Mol. Med. 2010, 88:1203-1211.
72. Ashlin T.G., Buckley M.L., Salter R.C., Johnson J.L., Kwan A.P.L., Ramji D.P. The anti-atherogenic cytokine interleukin-33 inhibits the expression of a disintegrin and metalloproteinase with thrombospondin motifs-1, -4 and -5 in human macrophages: Requirement of extracellular signal-regulated kinase, c-Jun N-terminal kinase and phosphoinositide 3-kinase signaling pathways. Int. J. Biochem. Cell Biol. 2014, 46:113-123.
73. Heo K.S., Cushman H.J., Akaike M., Woo C.H., Wang X., Qiu X., Fujiwara K., Abe J. ERK5 activation in macrophages promotes efferocytosis and inhibits atherosclerosis. Circulation 2014, 130:180-191.
74. Le N.T., Heo K.S., Takei Y., Lee H., Woo C.H., Chang E., et al. A crucial role for p90RSK-mediated reduction of ERK5 transcriptional activity in endothelial dysfunction and atherosclerosis. Circulation 2013, 127:486-499.
75. Komaravolu R.K., Adam C., Moonen J.R., Harmsen M.C., Goebeler M., Schmidt M. Erk5 inhibits endothelial migration via KLF2-dependent down-regulation of PAK1. Cardiovasc. Res. 2015, 105:86-95.
76. Mei S., Gu H., Ward A., Yang X., Guo H., He K., Liu Z., Cao W. p38 mitogen-activated protein kinase (MAPK) promotes cholesterol ester accumulation in macrophages through inhibition of macroautophagy. J. Biol. Chem. 2012, 287:11761-11768.
77. DeVries-Seimon T., Li Y.K., Yao P.M., Stone E., Wang Y.B., Davis R.J., Flavell R., Tabas I. Cholesterol-induced macrophage apoptosis requires ER stress pathways and engagement of the type A scavenger receptor. J. Cell Biol. 2005, 171:61-73.
78. Seimon T.A., Wang Y., Han S., Senokuchi T., Schrijvers D.M., Kuriakose G., Tall A.R., Tabas I.A. Macrophage deficiency of p38 alpha MAPK promotes apoptosis and plaque necrosis in advanced atherosclerotic lesions in mice. J. Clin. Invest. 2009, 119:886-898.
79. Kardakaris R., Gareus R., Xanthoulea S., Pasparakis M. Endothelial and macrophage-specific deficiency of p38α MAPK does not affect the pathogenesis of atherosclerosis in ApoE-/- Mice. PLoS ONE 2011, 6:e21055.
80. Ricci R., Sumara G., Sumara I., Rozenberg I., Kurrer M., Akhmedov A., et al. Requirement of JNK2 for scavenger receptor A-mediated foam cell formation in atherogenesis. Science 2004, 306:1558-1561.
81. Amini N., Boyle J.J., Moers B., Warboys C.M., Malik T.H., Zakkar M., Francis S.E., Mason J.C., Haskard D.O., Evans P.C. Requirement of JNK1 for endothelial cell injury in atherogenesis. Atherosclerosis 2014, 235:613-618.
82. Yoshimura K., Aoki H., Ikeda Y., Fujii K., Akiyama N., Furutani A., et al. Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase. Nat. Med. 2005, 11:1330-1338.
83. Wang J., An F.S., Zhang W., Gong L., Wie S.J., Qin W.D., Wang X.P., Zhao Y.X., Zhang Y., Zhang C., Zhang M.X. Inhibition of c-Jun N-terminal kinase attenuates low shear stress-induced atherogenesis in apolipoprotein E-deficient mice. Mol. Med. 2011, 17:990-991.
84. Mallavia B., Recio C., Oguiza A., Ortiz-Muñoz G., Lazaro I., Lopez-Parra V., Lopez-Franco O., Schindler S., Depping R., Egido J., Gomez-Guerrero C. Peptide inhibitor of NF-κB translocation ameliorates experimental atherosclerosis. Am. J. Pathol. 2013, 182:1910-1921.
85. Cuaz-Pérolin C., Billiet L., Baugé E., Copin C., Scott-Algara D., Genze F., Büchele B., Syrovets T., Simmet T., Rouis M. Antiinflammatory and antiatherogenic effects of the NF-kappaB inhibitor acetyl-11-keto-beta-boswellic acid in LPS-challenged ApoE-/- mice. Arterioscler. Thromb. Vasc. Biol. 2008, 28:272-277.
86. Wolfrum S., Teupser D., Tan M., Chen K.Y., Breslow J.L. The protective effect of A20 on atherosclerosis in apolipoprotein E-deficient mice is associated with reduced expression of NF-kappaB target genes. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:18601-18606.
87. Sun X., He S., Wara A.K., Icli B., Shvartz E., Tesmenitsky Y., et al. Systemic delivery of microRNA-181b inhibits nuclear factor-κB activation, vascular inflammation, and atherosclerosis in apolipoprotein E-deficient mice. Circ. Res. 2014, 114:32-40.
88. Wang Y., Wang G.Z., Rabinovitch P.S., Tabas I. Macrophage mitochondrial oxidative stress promotes atherosclerosis and nuclear factor-κB-mediated inflammation in macrophages. Circ. Res. 2014, 114:421-433.
89. Gareus R., Kotsaki E., Xanthoulea S., van der Made I., Gijbels M.J.J., Kardakaris R., Polykratis A., Kollias G., de Winther M.P., Pasparakis M. Endothelial cell-specific NF-kappa B inhibition protects mice from atherosclerosis. Cell Metab. 2008, 8:372-383.
90. Goossens P., Vergouwe M.N., Gijbels M.J., Curfs D.M., van Woezik J.H., Hoeksema M.A., Xanthoulea S., Leenen P.J., Rupec R.A., Hofker M.H., de Winther M.P. Myeloid IκBα deficiency promotes atherogenesis by enhancing leukocyte recruitment to the plaques. PLoS ONE 2011, 6:e22327.
91. Tilstam P.V., Gijbels M.J., Habbeddine M., Cudejko C., Asare Y., Theelen W., Zhou B., et al. Bone marrow-specific knock-in of a non-activatable Ikkα kinase mutant influences haematopoiesis but not atherosclerosis in Apoe-deficient mice. PLoS ONE 2014, 9:e87452.
92. Cao C., Zhu Y., Chen W., Li L., Qi Y., Wang X., Zhao Y., Wan X., Chen X. IKKε knockout prevents high fat diet induced arterial atherosclerosis and NF-κB signaling in mice. PLoS ONE 2013, 8:e64930.
93. Kanters E., Pasparakis M., Gijbels M.J., Vergouwe M.N., Partouns-Hedriks I., Fijneman R.J., et al. Inhibition of NF-kappaB activation in macrophages increases atherosclerosis in LDL receptor-deficient mice. J. Clin. Invest. 2003, 112:1176-1185.
94. Park S.H., Sui Y., Gizard F., Xu J., Rios-Pilier J., Helsley R.N., Han S.S., Zhou C. Myeloid-specific IκB kinase β deficiency decreases atherosclerosis in low-density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2012, 32:2869-2876.
95. Sui Y., Park S.H., Xu J., Monette S., Helsley R.N., Han S.S., Zhou C. IKKβ links vascular inflammation to obesity and atherosclerosis. J. Exp. Med. 2014, 211:869-886.
96. Wong M.C., van Diepen J.A., Hu L., Guigas B., de Boer H.C., van Puijvelde G.H., et al. Hepatocyte-specific IKKβ expression aggravates atherosclerosis development in APOE*3-Leiden mice. Atherosclerosis 2012, 220:362-368.
97. Kanters E., Gijbels M.J.J., van der Made I., Vergouwe M.N., Heeringa P., Kraal G., Hofker M.H., de Winther M.P. Hematopoietic NF-kappa B1 deficiency results in small atherosclerotic lesions with an inflammatory phenotype. Blood 2004, 103:934-940.
98. Ye X., Jiang X., Guo W., Clark K., Gao Z. Overexpression of NF-kappa B p65 in macrophages ameliorates atherosclerosis in apoE-knockout mice. Am. J. Physiol. Endocrinol. Metab. 2013, 305:E1375-E1383.
99. Lawrence T., Gilroy D.W., Colville-Nash P.R., Willoughby D.A. Possible new role for NF-kappaB in the resolution of inflammation. Nat. Med. 2001, 7:1291-1297.
100. Lawrence T., Fong C. The resolution of inflammation: Anti-inflammatory roles for NF-κB. Int. J. Biochem. Cell Biol. 2010, 42:519-523.
101. Chang J.D., Sukhova G.K., Libby P., Schvartz E., Lichtenstein A.H., Field S.J., Kennedy C., Madhavarapu S., Luo J., Wu D., Cantley L.C. Deletion of the phosphoinositide 3-kinase p110 gamma gene attenuates murine atherosclerosis. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:8077-8082.
102. Zotes T.M., Arias C.F., Fuster J.J., Spada R., Perez-Yaguee S., Hirsch E., Wymann M., Carrera A.C., Andrés V., Barber D.F. PI3K p110 gamma deletion attenuates murine atherosclerosis by reducing macrophage proliferation but not polarization or apoptosis in lesions. PLoS ONE 2013, 8:e72674.
103. Fougerat A., Gayral S., Gourdy P., Schambourg A., Rueckle T., Schwarz M.K., et al. Genetic and pharmacological targeting of phosphoinositide 3-kinase-gamma reduces atherosclerosis and favors plaque stability by modulating inflammatory processes. Circulation 2008, 117:1310-1317.
104. Siragusa M., Katare R., Meloni M., Damilano F., Hirsch E., Emanueli C., Madeddu P. Involvement of phosphoinositide 3-kinase gamma in angiogenesis and healing of experimental myocardial infarction in mice. Circ. Res. 2010, 106:757-768.
105. Fernández-Hernando C., Ackah E., Yu J., Suárez Y., Murata T., Iwakiri Y., Prendergast J., Miao R.Q., Birnbaum M.J., Sessa W.C. Loss of Akt1 leads to severe atherosclerosis and occlusive coronary artery disease. Cell Metab. 2007, 6:446-457.
106. Fernández-Hernando C., József L., Jenkins D., Di Lorenzo A., Sessa W.C. Absence of Akt1 reduces vascular smooth muscle cell migration and survival and induces features of plaque vulnerability and cardiac dysfunction during atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2009, 29:2033-2040.
107. Babaev V.R., Hebron K.E., Wiese C.B., Toth C.L., Ding L., Zhang Y., May J.M., Fazio S., Vickers K.C., Linton M.F. Macrophage deficiency of Akt2 reduces atherosclerosis in Ldlr null mice. J. Lipid Res. 2014, 55:2296-2308.
108. Rensing K.L., de Jager S.C., Stroes E.S., Vos M., Twickler M.T., Dallinga-Thie G.M., de Vries C.J., Kuiper J., Bot I., von der Thüsen J.H. Akt2/LDLr double knockout mice display impaired glucose tolerance and develop more complex atherosclerotic plaques than LDLr knockout mice. Cardiovasc. Res. 2014, 101:277-287.
109. Ding L., Biswas S., Morton R.E., Smith J.D., Hay N., Byzova T.V., Febbraio M., Podrez E.A. Akt3 deficiency in macrophages promotes foam cell formation and atherosclerosis in mice. Cell Metab. 2012, 15:861-872.
110. Randolph G.J. Mechanisms that regulate macrophage burden in atherosclerosis. Circ. Res. 2014, 114:1757-1771.
111. Swirski F.K., Libby P., Aikawa E., Alcaide P., Luscinskas F.W., Weissleder R., Pittet M.J. Ly-6C(hi) monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J. Clin. Invest. 2007, 117:195-205.
112. Gui T., Shimokado A., Sun Y., Akasaka T., Muragaki Y. Diverse roles of macrophages in atherosclerosis: From inflammatory biology to biomarker discovery. Mediat. Inflamm. 2012, 2012:693083.
113. Robbins C.S., Hilgendorf I., Weber G.F., Theurl I., Iwamoto Y., Figueiredo J.L., et al. Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat. Med. 2013, 19:1166-1172.
114. Letinger N., Schulman I.G. Phenotypic polarization of macrophages in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2013, 33:1120-1126.
115. Wolfs I.M.J., Donners M.M.P.C., de Winther M.P.J. Differentiation factors and cytokines in the atherosclerotic plaque micro-environment as a trigger for macrophage polarisation. Thromb. Haemost. 2011, 106:763-771.
116. Colin S., Chinett-Gbaguidi G., Staels B. Macrophage phenotypes in atherosclerosis. Immunol. Rev. 2014, 262:153-166.
117. Gleissner C.A., Shaked I., Little K., Ley K. CXC chemokine ligand 4 induces a unique transcriptome in monocyte-derived macrophages. J. Immunol 2010, 184:4810-4818.
118. Sachais B.S., Turrentine T., McKenna J.M.D., Rux A.H., Rader D., Kowalska M.A. Elimination of platelet factor 4 (PF4) from platelets reduces atherosclerosis in C57BI/6 and apoE(-/-) mice. Thromb. Haemost. 2007, 98:1108-1113.
119. Niessner A., Weyand C.M. Dendritic cells in atherosclerotic disease. Clin. Immunol. 2010, 134:25-32.
120. Shaposhnik Z., Wang X., Weinstein M., Bennett B.J., Lusis A.J. Granulocyte macrophage colony-stimulating factor regulates dendritic cell content of atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 2007, 27:621-627.
121. Chistiakov D.A., Sobenin I.A., Orekhov A.N., Bobryshev Y.V. Dendritic cells in atherosclerotic inflammation: the complexity of functions and the peculiarities of pathophysiological effects. Front. Physiol. 2014, 5:196.
122. Ait-Oufella H., Sage A.P., Mallat Z., Tedgui A. Adaptive (T and B cells) immunity and control by dendritic cells in atherosclerosis. Circ. Res. 2014, 114:1640-1660.
123. Macritchie N., Grassia G., Sabir S.R., Maddaluno M., Welsh P., Sattar N., et al. Plasmacytoid dendritic cells play a key role in promoting atherosclerosis in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2012, 32:2569-2579.
124. Sage A., Murphy D.M., Maffia P., Masters L.M., Sabir S.R., Baker L.L., et al. MHC class II-restricted antigen presentation by plasmacytoid dendritic cells drives pro-atherogenic T cell immunity. Circulation 2014, 130:1363-1373.
125. Daissormont I.T., Christ A., Temmerman L., Sampedro Millares S., Seijkens T., Manca M., et al. Plasmacytoid dendritic cells protect against atherosclerosis by tuning T-cell proliferation and activity. Circ. Res. 2011, 109:1387-1395.
126. Paulson K.E., Zhu S.N., Chen M., Nurmohamed S., Jongstra-Bilen J., Cybulsky M.L. Resident intimal dendritic cells accumulate lipid and contribute to the initiation of atherosclerosis. Circ. Res. 2010, 106:383-390.
127. Habets K.L., van Puijvelde G.H., van Duivenvoorde L.M., van Wanrooij E.J., de Vos P., Tervaert J.W., van Berkel T.J., Toes R.E., Kuiper J. Vaccination using oxidized low-density lipoprotein-pulsed dendritic cells reduces atherosclerosis in LDL receptor-deficient mice. Cardiovasc. Res. 2010, 85:622-630.
128. Hermansson A., Johansson D.K., Ketelhuth D.F., Andersson J., Zhou X., Hansson G.K. Immunotherapy with tolerogenic apolipoprotein B-100-loaded dendritic cells attenuates atherosclerosis in hypercholesteromic mice. Circulation 2011, 123:1083-1091.
129. Agrawal S., Febbraio M., Podrez E., Cathcart M.K., Stark G.R., Chisolm G.M. Signal transducer and activator of transcription 1 is required for optimal foam cell formation and atherosclerotic lesion development. Circulation 2007, 115:2939-2947.
130. Lim W.S., Timmins J.M., Seimon T.A., Sadler A., Kolodgie F.D., Virmani R., Tabas I. Signal transducer and activator of transcription-1 is critical for apoptosis in macrophages subjected to endoplasmic reticulum stress in vitro and in advanced atherosclerotic lesions in vivo. Circulation 2008, 117:940-951.
131. Taleb S., Tedgui A., Mallat Z. IL-17 and Th17 cells in atherosclerosis: subtle and contextual roles. Arterioscler. Thromb. Vasc. Biol. 2015, 35:258-264.
132. Singh N.N., Ramji D.P. The role of transforming growth factor-beta in atherosclerosis. Cytokine Growth Factor Rev. 2006, 17:487-499.
133. Shah P.K., Chyu K., Dimayuga P.C., Nilsson J. Vaccine for atherosclerosis. J. Am. Coll. Cardiol. 2014, 64:2779-2791.
134. To K., Agotis A., Besra G., Bobik A., Toh B.H. NKT cell subsets mediate differential proatherogenic effects in ApoE-/- mice. Arterioscler. Thromb. Vasc. Biol. 2009, 29:671-677.
135. Selathurai A., Deswaerte V., Kanellakis P., Tipping P., Toh B.H., Bobik A., Kyaw T. Natural killer (NK) cells augment atherosclerosis by cytotoxic-dependent mechanisms. Cardiovasc. Res. 2014, 102:128-137.
136. Döring Y., Drechsler M., Soehnlein O., Weber C. Neutrophils in atherosclerosis: From mice to man. Arterioscler. Thromb. Vasc. Biol. 2015, 35:288-295.
137. Tsiantoulas D., Diehl C.J., Witztum J.L., Binder C.J. B cells and humoral immunity in atherosclerosis. Circ. Res. 2014, 114:1743-1756.
138. Kyaw T., Tipping P., Bobik A., Toh B.H. Protective role of natural IgM-producing B1a cells in atherosclerosis. Trends Cardiovasc. Med. 2012, 22:48-53.
139. Hilgendorf I., Theurl I., Gerhardt L.M., Robbins C.S., Weber G.F., Gonen A., et al. Innate response activator B cells aggravate atherosclerosis by stimulating T helper-1 adaptive immunity. Circulation 2014, 129:1677-1687.
140. Bot I., de Jager S.C.A., Zernecke A., Lindstedt K.A., van Berkel T.J.C., Weber C., Biessen E.A.L. Perivascular mast cells promote atherogenesis and induce plaque destabilization in apolipoprotein E-deficient mice. Circulation 2007, 115:2516-2525.
141. Sun J., Sukhova G.K., Wolters P.J., Yang M., Kitamoto S., Libby P., MacFarlane L.A., et al. Mast cells promote atherosclerosis by releasing proinflammatory cytokines. Nat. Med. 2007, 13:719-724.
142. Ait-Oufella H., Taleb S., Mallat Z., Tedgui A. Recent advances on the role of cytokines in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2011, 31:969-979.
143. Kleemann R., Zadelaar S., Kooistra T. Cytokines and atherosclerosis: a comprehensive review of studies in mice. Cardiovasc. Res. 2008, 79:360-376.
144. Tedgui A., Mallat Z. Cytokines in atherosclerosis: Pathogenic and regulatory pathways. Physiol. Rev. 2006, 86:515-581.
145. Bond M., Chase A.J., Baker A.H., Newby A.C. Inhibition of transcription factor NF-kappa B reduces matrix metalloproteinase-1,-3 and-9 production by vascular smooth muscle cells. Cardiovasc. Res. 2001, 50:556-565.
146. Gupta S., Pablo A.M., Jiang X.C., Wang N., Tall A.R., Schindler C. IFN-gamma potentiates atherosclerosis in apoE knock-out mice. J. Clin. Invest. 1997, 99:2752-2761.
147. Buono C., Come C.E., Stavrakis G., Maguire G.G., Connelly P.W., Lichtman A.H. Influence of interferon-gamma on the extent and phenotype of diet-induced atherosclerosis in the LDLR-deficient mouse. Arterioscler. Thromb. Vasc. Biol. 2003, 23:454-460.
148. Whitman S.C., Ravisankar P., Elam H., Daugherty A. Exogenous interferon-gamma enhances atherosclerosis in apolipoprotein E-/- mice. Am. J. Pathol. 2000, 157:1819-1824.
149. Koga M., Kai H., Yasukawa H., Yamamoto T., Kawai Y., Kato S., Kusaba K., Kai M., Egashira K., Kataoka Y., Imaizumi T. Inhibition of progression and stabilization of plaques by postnatal interferon-gamma function blocking in ApoE-knockout mice. Circ. Res. 2007, 101:348-356.
150. Xanthoulea S., Thelen M., Pöttgens C., Gijbels M.J., Lutgens E., de Winther M.P. Absence of p55 TNF receptor reduces atherosclerosis, but has no major effect on angiotensin II induced aneurysms in LDL receptor deficient mice. PLoS ONE 2009, 7:e6113.
151. Xiao N., Yin M., Zhang L., Qu X., Du H., Sun X., et al. Tumor necrosis factor-alpha deficiency retards early fatty-streak lesion by influencing the expression of inflammatory factors in apoE-null mice. Mol. Genet. Metab. 2009, 96:239-244.
152. Ohta H., Wada H., Niwa T., Kirii H., Iwamoto N., Fujii H., Saito K., Sekikawa K., Seishima M. Disruption of tumor necrosis factor-alpha gene diminishes the development of atherosclerosis in ApoE-deficient mice. Atherosclerosis 2005, 180:11-17.
153. Kirii H., Niwa T., Yamada Y., Wada H., Saito K., Iwakura Y., Asano M., Moriwaki H., Seishima M. Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2003, 23:656-660.
154. Chamberlain J., Francis S., Brookes Z., Shaw G., Graham D., Alp N.J., Dower S., Crossman D.C. Interleukin-1 regulates multiple atherogenic mechanisms in response to fat feeding. PLoS ONE 2009, 4:e5073.
155. Devlin C.M., Kuriakose G., Hirsch E., Tabas I. Genetic alterations of IL-1 receptor antagonist in mice affect plasma cholesterol level and foam cell lesion size. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:6280-6285.
156. Merhi-Soussi F., Kwak B.R., Magne D., Chadjichristos C., Berti M., Pelli G., James R.W., Mach F., Gabay C. Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice. Cardiovasc. Res. 2005, 66:583-593.
157. Elhage R., Jawien J., Rudling M., Ljunggren H.G., Takeda K., Akira S., Bayard F., Hansson G.K. Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice. Cardiovasc. Res. 2003, 59:234-240.
158. Tenger C., Sundborger A., Jawien J., Zhou X. IL-18 accelerates atherosclerosis accompanied by elevation of IFN-gamma and CXCL16 expression independently of T cells. Arterioscler. Thromb. Vasc. Biol. 2005, 25:791-796.
159. Whitman S.C., Ravisankar P., Daugherty A. Interleukin-18 enhances atherosclerosis in apolipoprotein E(-/-) mice through release of interferon-gamma. Circ. Res. 2002, 90:E34-E38.
160. Mallat Z., Corbaz A., Scoazec A., Graber P., Alouani S., Esposito B., Humbert Y., Chvatchko Y., Tedgui A. Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability. Circ. Res. 2001, 89:E41-E45.
161. Caligiuri C., Rudling M., Ollivier V., Jacob M.P., Michel J.B., Hansson G.K., Nicoletti A. Interleukin-10 deficiency increases atherosclerosis, thrombosis, and low-density lipoproteins in apolipoprotein E knockout mice. Mol. Med. 2003, 9:10-17.
162. Liu Y., Li D., Chen J., Xie J., Bandyopadhyay S., Zhang D., Nemarkommula A.R., Liu H., Mehta J.L., Hermonat P.L. Inhibition of atherogenesis in LDLR knockout mice by systemic delivery of adeno-associated virus type 2-hIL-10. Atherosclerosis 2006, 188:19-27.
163. Yoshioka T., Okada T., Maeda Y., Ikeda U., Shimpo M., Nomoto T., et al. Adeno-associated virus vector-mediated interleukin-10 gene transfer inhibits atherosclerosis in apolipoprotein E-deficient mice. Gene Ther. 2004, 11:1772-1779.
164. Namiki M., Kawashima S., Yamashita T., Ozaki M., Sakoda T., Inoue N., Hirata K., Morishita R., Kaneda Y., Yokoyama M. Intramuscular gene transfer of interleukin-10 cDNA reduces atherosclerosis in apolipoprotein E-knockout mice. Atherosclerosis 2004, 172:21-29.
165. Mallat Z., Gojova A., Marchiol-Fournigault C., Esposito B., Kamate˙ C., Merval R., Fradelizi D., Tedgui A. Inhibition of transforming growth factor-beta signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ. Res. 2001, 89:930-934.
166. Robertson A.K., Rudling M., Zhou X., Gorelik L., Flavell R.A., Hansson G.K. Disruption of TGF-beta signaling in T cells accelerates atherosclerosis. J. Clin. Invest. 2003, 112:1342-1350.
167. Gisterá A., Robertson A.K., Andersson J., Ketelhuth D.F., Ovchinnikova O., Nilsson S.K., Lundberg A.M., Li M.O., Flavell R.A., Hansson G.K. Transforming growth factor-β signaling in T cells promotes stabilization of atherosclerotic plaques through an interleukin-17-dependent pathway. Sci. Transl. Med. 2013, 5. (196ra100).
168. Reifenberg K., Cheng F., Orning C., Crain J., Küpper I., Wiese E., Protschka M., Blessing M., Lackner K.J., Torzewski M. Overexpression of TGF-β1 in macrophages reduces and stabilizes atherosclerotic plaques in ApoE-deficient mice. PLoS ONE 2012, 7:e40990.
169. Frutkin A.D., Otsuka G., Stempien-Otero A., Sesti C., Du L., Jaffe M., et al. TGF-[beta]1 limits plaque growth, stabilizes plaque structure, and prevents aortic dilation in apolipoprotein E-null mice. Arterioscler. Thromb. Vasc. Biol. 2009, 29:1251-1257.
170. Miller A.M., Xu D., Asquith D.L., Denby L., Li Y., Sattar N., et al. IL-33 reduces the development of atherosclerosis. J. Exp. Med. 2008, 205:339-346.
171. McLaren J.E., Michael D.R., Salter R.C., Ashlin T.G., Calder C.J., Miller A.M., Liew F.Y., Ramji D.P. IL-33 reduces macrophage foam cell formation. J. Immunol. 2010, 185:1222-1229.
172. Michael D.R., Salter R.C., Ramji D.P. TGF-β inhibits the uptake of modified low density lipoprotein by human macrophages through a Smad-dependent pathway: a dominant role for Smad-2. Biochim. Biophys. Acta 2012, 1822:1608-1616.
173. Miller A.M. Role of IL-33 in inflammation and disease. J. Inflamm. 2011, 8:22.
174. Miller A.M., Liew F.Y. The IL-33/ST2 pathway - A new therapeutic target in cardiovascular disease. Pharmacol. Ther. 2011, 131:179-186.
175. Schmitz J., Owyang A., Oldham E., Song Y.L., Murphy E., McClanahan T.K., et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005, 23:479-490.
176. Dinarello C.A. An IL-1 family member requires caspase-1 processing and signals through the ST2 receptor. Immunity 2005, 23:461-462.
177. Lefrançais E., Cayrol C. Mechanisms of IL-33 processing and secretion: differences and similarities between IL-1 family members. Eur. Cytokine Netw. 2012, 23:120-127.
178. Lüthi A.U., Cullen S.P., McNeela E.A., Duriez P.J., Afonina I.S., Sheridan C., et al. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity 2009, 31:84-98.
179. Ali S., Mohs A., Thomas M., Klare J., Ross R., Schmitz M.L., Martin M.U. The dual function cytokine IL-33 interacts with the transcription factor NF-kappa B to dampen NF-kappa B-stimulated gene transcription. J. Immunol. 2011, 187:1609-1616.
180. Carriere V., Roussel L., Ortega N., Lacorre D.A., Americh L., Aguilar L., Bouche G., Girard J.P. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:282-287.
181. Wasserman A., Ben-Shoshan J., Entin-Meer M., Maysel-Auslender S., Guzner-Gur H., Keren G. Interleukin-33 augments Treg cell levels: a flaw mechanism in atherosclerosis. Isr. Med. Assoc. J. 2012, 14:620-623.
182. Seki K., Sanada S., Kudinova A.Y., Steinhauser M.L., Handa V., Gannon J., Lee R.T. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ. Heart Fail. 2009, 2:684-691.
183. Sanada S., Hakuno D., Higgins L.J., Schreiter E.R., McKenzie A.N.J., Lee R.T. IL-33 and ST2 comprise a critical biomechanically induced and card ioprotective signaling system. J. Clin. Invest. 2007, 117:1538-1549.
184. Liu C.-L., Shen D.-L., Kui Z., Tang J.-N., Hai Q.-M., Zhang J.-Y. Levels of interleukin-33 and interleukin-6 in patients with acute coronary syndrome or stable angina. Clin. Invest. Med. 2013, 36:E234-E241.
185. Zhang H.-F., Xie S.-L., Chen Y.-X., Mai J.-T., Wang J.-F., Zhu W.-L., Zhu L.-G. Altered serum levels of IL-33 in patients with advanced systolic chronic heart failure: correlation with oxidative stress. J. Transl. Med. 2012, 10:120.
186. Weinberg E.O., Shimpo M., De Keulenaer G.W., MacGillivray C., Tominaga S., Solomon S.D., Rouleau J.L., Lee R.T. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 2002, 106:2961-2966.
187. Chen L.Q., de Lemos J.A., Das S.R., Ayers C.R., Rohatgi A. Soluble ST2 is associated with all-cause and cardiovascular mortality in a population-based cohort: The Dallas Heart Study. Clin. Chem. 2013, 59:536-546.
188. Weir R.A.P., Miller A.M., Murphy G.E.J., Clements S., Steedman T., Connell J.M.C., McInnes I.B., Dargie H.J., McMurray J.J. Serum soluble ST2 a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J. Am. Coll. Cardiol. 2010, 55:243-250.
189. Januzzi J.L., Peacock W.F., Maisel A.S., Chae C.U., Jesse R.L., Baggish A.L., et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (pro-brain natriuretic peptide investigation of dyspnea in the emergency department) study. J. Am. Coll. Cardiol. 2007, 50:607-613.
190. Libby P., Ridker P.M., Hansson G.K. Progress and challenges in translating the biology of atherosclerosis. Nature 2011, 473:317-325.
191. Do R.Q., Nicholls S.J., Schwartz G.G. Evolving targets for lipid-modifying therapy. EMBO Mol. Med. 2014, 6:1215-1230.
192. Aryal B., Rotllan N., Fernández-Hernando C. Noncoding RNAs and atherosclerosis. Curr. Atheroscler. Rep. 2014, 16:407.